These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 34372537)

  • 1. Advances in Phage Therapy: Targeting the
    Lauman P; Dennis JJ
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Interactions among
    Lauman P; Dennis JJ
    Microbiol Spectr; 2023 Jun; 11(3):e0443022. PubMed ID: 37195168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS): antibiotics stimulate lytic phage activity.
    Kamal F; Dennis JJ
    Appl Environ Microbiol; 2015 Feb; 81(3):1132-8. PubMed ID: 25452284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cangene gold medal award lecture - Genomic analysis and modification of Burkholderia cepacia complex bacteriophages.
    Lynch KH; Dennis JJ
    Can J Microbiol; 2012 Mar; 58(3):221-35. PubMed ID: 22339239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of neutrophil defects on Burkholderia cepacia complex pathogenesis.
    Porter LA; Goldberg JB
    Front Cell Infect Microbiol; 2011; 1():9. PubMed ID: 22919575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burkholderia contaminans Bacteriophage CSP3 Requires O-Antigen Polysaccharides for Infection.
    Stanton CR; Batinovic S; Petrovski S
    Microbiol Spectr; 2023 Jun; 11(3):e0533222. PubMed ID: 37199610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Bacterial Cytoskeleton of the
    Carnell SC; Perry JD; Borthwick L; Vollmer D; Biboy J; Facchini M; Bragonzi A; Silipo A; Vergunst AC; Vollmer W; Khan ACM; De Soyza A
    Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29848957
    [No Abstract]   [Full Text] [Related]  

  • 8. [Advances in virulence determinants in Burkholderia cepacia complex--a review].
    Tang Q; Zhu H; Qin W
    Wei Sheng Wu Xue Bao; 2014 May; 54(5):487-97. PubMed ID: 25199247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant
    Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burkholderia cepacia complex: beyond pseudomonas and acinetobacter.
    Gautam V; Singhal L; Ray P
    Indian J Med Microbiol; 2011; 29(1):4-12. PubMed ID: 21304187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promise of bacteriophage therapy for Burkholderia cepacia complex respiratory infections.
    Semler DD; Lynch KH; Dennis JJ
    Front Cell Infect Microbiol; 2011; 1():27. PubMed ID: 22919592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic sequence and activity of KS10, a transposable phage of the Burkholderia cepacia complex.
    Goudie AD; Lynch KH; Seed KD; Stothard P; Shrivastava S; Wishart DS; Dennis JJ
    BMC Genomics; 2008 Dec; 9():615. PubMed ID: 19094239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.
    Semler DD; Goudie AD; Finlay WH; Dennis JJ
    Antimicrob Agents Chemother; 2014 Jul; 58(7):4005-13. PubMed ID: 24798268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology.
    Mahenthiralingam E; Baldwin A; Dowson CG
    J Appl Microbiol; 2008 Jun; 104(6):1539-51. PubMed ID: 18217926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [An opportunistic pathogen frequently isolated from immunocompromised patients: Burkholderia cepacia complex].
    Baylan O
    Mikrobiyol Bul; 2012 Apr; 46(2):304-18. PubMed ID: 22639321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenicity, virulence factors, and strategies to fight against Burkholderia cepacia complex pathogens and related species.
    Leitão JH; Sousa SA; Ferreira AS; Ramos CG; Silva IN; Moreira LM
    Appl Microbiol Biotechnol; 2010 Jun; 87(1):31-40. PubMed ID: 20390415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection.
    Martina P; Feliziani S; Juan C; Bettiol M; Gatti B; Yantorno O; Smania AM; Oliver A; Bosch A
    Int J Med Microbiol; 2014 Nov; 304(8):1182-91. PubMed ID: 25217078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental bacteriophage therapy increases survival of Galleria mellonella larvae infected with clinically relevant strains of the Burkholderia cepacia complex.
    Seed KD; Dennis JJ
    Antimicrob Agents Chemother; 2009 May; 53(5):2205-8. PubMed ID: 19223640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance of the Burkholderia cepacia complex to fosmidomycin and fosmidomycin derivatives.
    Messiaen AS; Verbrugghen T; Declerck C; Ortmann R; Schlitzer M; Nelis H; Van Calenbergh S; Coenye T
    Int J Antimicrob Agents; 2011 Sep; 38(3):261-4. PubMed ID: 21724375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of essential oils against multidrug-resistant clinical isolates of the Burkholderia cepacia complex.
    Vasireddy L; Bingle LEH; Davies MS
    PLoS One; 2018; 13(8):e0201835. PubMed ID: 30071118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.